WORLD-RENOWNED STEM CELL RESEARCHER, BRIAN MEHLING, MD, SET TO ATTEND THE ANNUAL WORLD ECONOMIC FORUM IN DAVOS

ZURICH, Switzerland – May 4, 2022 – Brian Mehling, MD, a world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, board-certified in anti-aging medicine, and founder of Blue Horizon International (BHI), will be attending the Annual World Economic Forum (WEF) in Davos from May 22-26. This will be Dr. Mehling’s ninth year attending the global conference.

The 52nd Annual Meeting will convene on the theme “Working Together, Restoring Trust,” with the aim to address economic, environmental, political and social fault-lines exacerbated by the COVID-19 pandemic.
Dr. Mehling and his team will be available onsite to share insights on the current and upcoming breakthroughs within the stem cells arena, as pertinent to the technology revolution and the future of the world.

“Stem cell therapies are, without a doubt, the future of medicine. I believe they will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” shared Dr. Brian Mehling, Founder of Blue Horizon International. “The importance of research and the key direction that it will take will truly shape the way patients with chronic conditions, disorders, and acute diseases are treated.”

WEF began as a forum to generate ideas and solutions to help shape the global, regional, and industry agendas. The event attracts top-level business leaders from all over the world. Attendees include C-suite executives from corporations, heads of state and government, leaders of international organizations, civil society and religious organizations, academia, the media, and the arts.

Onsite interviews with Dr. Mehling at WEF will be available upon request and handled on a first-come, first-serve basis. To learn more about WEF, please visit: http://www.weforum.org

About Blue Horizon International
Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research, and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information, please visit Blue Horizon International at www.bluehorizoninternational.com.
Media contact: knovakova@bluehorizoninternational.com

Blue Horizon International and Mehling Orthopedics to exhibit at American Academy Of Orthopaedic Surgeons Annual Meeting in Chicago

Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons in Chicago, Illinois from March 22-26, 2022 at the McCormick Place Convention Center. The booth number is 1904.

This is the world’s largest meeting of orthopaedic surgeons, researchers, and allied health professionals. The meeting offers physicians the opportunity to exchange ideas with their colleagues and learn about cutting-edge technology in their field.

Dr. Mehling is also the chief medical officer at BHI Therapeutic Sciences, LLC, a company that offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including mesenchymal stem cells and Wharton’s Jelly mesenchymal stem cells. 

BHI Therapeutic Sciences and Blue Horizon International (BHI) will exhibit at the conference to introduce data outcomes from its program located at Malacky Hospital in Slovakia. 

“Stem cell therapy is primarily intended for patients with a diagnosis of joint osteoarthritis, whether being a gonarthrosis or coxarthrosis of first and second degree. Malacky Hospital is the only medical institute performing treatment of hip and knee osteoarthrosis with stem cells using the technology of BHI,” said Dr. Mehling.

Doreen Santora, CEO of BHI and BHI Therapeutic Sciences, LLC, who will be also attending the AAOS meeting added, “Malacky Hospital is a private hospital located in the western part of Slovakia, just a short car ride from Vienna. It offers high-quality, comprehensive, and customized healthcare solutions to organizations and individuals and it is staffed with expertly-trained medical professionals and is one of the premiere hospitals in Central Europe.”

Mehling Orthopedics performs complex orthopedic fracture surgeries, including high velocity fractures, open fractures and complex pelvic ring injuries as well as general orthopedic and sports medicine surgeries.  Their team of experts delivers specialized care for orthopedic traumatic injuries. With all doctors certified by the American Board of Orthopedic Surgeons, they are committed to providing the finest medical care possible. For more information, please visit www.mehlingorthopedics.com.

BHI Therapeutic Sciences, LLC is currently offering cord blood, Wharton’s Jelly mesenchymal stem cells, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and in Jamaica. More information, please visit www.bhisciences.com.


The American Academy of Orthopaedic Surgeons (AAOS) provides education and practice management services for orthopaedic surgeons and allied health professionals. The Academy serves as an advocate for improved patient care and informs the public about the science of orthopaedics and it serves more than 39,000 members worldwide. For more information, please visit www.aaos.org.

Brian Mehling, MD slated to participate in the 19th Annual World Congress of Society for Brain Mapping and Therapeutics

Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy meeting being held in LA March 10-13

Brian Mehling, MD, founder and chief medical officer of BHI Therapeutic Sciences, will virtually present on three topics at the 19th Annual World Congress of Society for Brain Mapping and Therapeutics. The meeting, entitled Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy, will be held at the Los Angeles Convention Center, March 10-13.


Dr. Mehling will speak on the following: Safety study of Cultured Wharton’s Jelly Mesenchymal Stem Cells, Umbilical cord-derived stem cell therapy for multiple sclerosis treatment – a single subject case study, and Mesenchymal stem cell therapy for drowning induced hypoxic brain injury – A pediatric case report study of recovery.

Dr. Mehling is a board-certified American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells. He is also board-certified in anti-aging and regenerative medicine.
“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. He and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.


This program is jointly Sponsored by Johns Hopkins University School of Medicine and Saint Louis University School of Medicine for Continuing Medical Education (CME) including 700+ presentations (live and virtual),13 keynotes, three panel discussions, and two bio-skills labs (Brain and Spine).

BHI Therapeutic Sciences (BHITS) is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).
Stem cells are a special kind of cell that can be used to regenerate the human body
without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.


Media Contact
Doreen Santora 201-342-7662
dsantora@bluehorizoninternational.com

BHI CEO Participates in Patient Safety Workshop Sponsored by the Joint Commission

Doreen Santora, RN, MHA

Doreen Santora, RN, MHA, chief executive officer of Blue Horizon International (BHI) and its subsidiaries, including BHI Therapeutic Sciences, recently participated the Joint Commission International (JCI) program titled Managing Patient Safety Events: A Root Cause Analysis Workshop.


The two-day, live virtual workshop provided participants with the knowledge, skills, and strategies to establish a standardized approach to managing patient safety events, including sentinel events.


“BHI Therapeutic Sciences is committed to providing the highest quality and safest care,” said Brian Mehling, MD, founder and chief medical officer of BHI. “I applaud our leadership and our team for always seeking new information and education in order to provide better clinical outcomes and experiences for our patients,” he said.
Doreen Santora has more than 30 years of healthcare management experience. A registered nurse with a Master of Science degree in health administration, she serves as the Chief Executive Officer of Blue Horizon International (BHI) and all its subsidiaries. Most recently, Ms. Santora was recognized as a top nurse by the International Nurses Association and is featured in the publication Worldwide Leaders in Healthcare. She received this honor for her outstanding achievements, commitment to education, and demonstrated leadership in her field.


BHI specializes in bringing quality stem cell, regenerative, and related biologic technologies and therapies to emerging and established markets in a safe and ethical manner. She is responsible for the oversight of the day-to-day operations of BHI and places a strong emphasis on quality assurance and patient satisfaction.


Under her leadership, BHI has opened two successful stem cell therapy clinics in Jamaica and Slovakia.
Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment. Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center. She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions.


The Joint Commission is the recognized global leader for healthcare accreditation. JCI is the author of rigorous international standards on quality and patient safety. These standards serve as the foundation of an evaluation process that helps healthcare organizations measure, assess, and continuously improve performance.

BRIAN MEHLING, MD EARNS ANTI-AGING AND REGENERATIVE MEDICINE BOARD CERTIFICATION

Brian Mehling, MD has successfully completed all components of the Board Certification in the field of Anti-Aging and Regenerative Medicine.
Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He spearheads groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.
“Cellular medicine is in high demand and stem cells have the potential to treat a wide range of diseases. Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. In addition, stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue.”
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).
Founded in 1992 by Dr. Ronald Klatz and Dr. Robert Goldman, The American Academy of Anti-Aging Medicine (A4M) is rooted in a forward-focused mission to redefine modern medicine, The American Academy of Anti-Aging Medicine (A4M) is the established global leader for continuing medical education in longevity medicine, metabolic resilience, and whole-person care.

Brian Mehling, M.D., and team travel to Monaco for potential investors

Brian Mehling, M.D., M.S.founder and chief medical officer of Blue Horizon International (BHI) and his team traveled to Monaco and Paris, France in November 2021, attending a series of meetings with potential investors and partners to expand access to stem cell therapeutics.

#BlueHorizonStemCells #StemCellTherapy #Monaco #France

Brian Mehling, M.D. and his team attended the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) at the San Diego Convention Center

Brian Mehling, M.D. and his team attended the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) at the San Diego Convention Center, CA from August 31- September 3, 2021.
AAOS is the world’s largest meeting of orthopaedic surgeons, researchers, and allied health professionals.
Dr. Mehling is the chief medical officer at BHI Therapeutic Sciences, LLC, a company that offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including mesenchymal stem cells.
BHI Therapeutic Sciences exhibited at the conference data outcomes from its program located at Malacky Hospital in Slovakia.
BHI is fully licensed by the Ministry of Health of the Slovak Republic to provide adipose stem cell therapies for orthopedic joint applications – knees, hips, shoulders, and ankles. Procedures utilize cutting-edge technology and adult stem cells only.
“Stem cell therapy is primarily intended for patients with a diagnosis of joint osteoarthritis, whether being a gonarthrosis or coxarthrosis of first and second degree. Malacky Hospital is the only medical institute performing treatment of hip and knee osteoarthrosis with stem cells using the technology of BHI,” said Dr. Mehling.
Doreen Santora, CEO of BHI Therapeutic Sciences also attended the AAOS meeting added, “Malacky Hospital is a private hospital located in the western part of Slovakia, just a short car ride from Vienna. It offers high-quality, comprehensive, and customized healthcare solutions to organizations and individuals and it is staffed with expertly-trained medical professionals and is one of the premiere hospitals in Central Europe.”

Chelsea Film Festival

Brian Mehling, M.D. hosted a gathering for filmmakers during the Chelsea Film Festival at his home in New York City on Friday October 15, 2021.
Dr. Mehling is also a documentary film producer. He is president and CEO of Industrial Motion Pictures (IMP), producer of the film Tiny Tears, which debuted at the prestigious Cannes Film Festival. Their newest film, titled “Stem Cells: The Revolution Is Here” was part of the Chelsea Film Festival this year.
#DrBrianMehling #BlueHorizonStemCells
#ChelseaFilmFestival #CFFNY2021

Brian Mehling, MD presented at the Annual Congress of Society for Brain Mapping & Therapeutics in Los Angeles

World leading translational neuroscience foundation highlighted the pioneering scientific, technological, advocacy, and policy work at the Ritz Carlton/JW Marriott in Downtown LA on July 10, 2021

The conference was the first in-person major medical conference in California after the state reopened.
Dr. Brian Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.
Dr. Mehling presented two talks in two sessions: “Session in Innovation in Spine Surgery” where his talk title was ” Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
The objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. “Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group,” Dr. Mehling said.
The second session was in Neurovascular Disorders and Dr.Mehling talk’s title was “Stem Cells and Stroke Recovery: A Retrospective Study.” Dr. Mehling presented the results of a study using Human umbilical cord blood cell therapy to treat stroke. Ninety-seven research subjects with ischemic and hemorrhagic stroke showed significant improvement of mobility of upper and lower extremities, muscle strength of upper and lower limbs and neurological function after therapy.

In addition, Dr.Mehling co-chaired a stem cell session (Session A26 – Stem Cell).

BHI Therapeutic Sciences (BHITS) is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).
Stem cells are a special kind of cell that can be used to regenerate the human body
without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.
Brain Mapping Foundation (BMF) was established in 2003 to help fast-tracking diagnostics and therapeutics for wounded soldiers, veterans, and civilians with neurological, spine, and neuro-psychiatric disorders. Since then, the organization has been pioneering lifesaving therapeutics and introducing trailblazing initiatives such as Neuroscience20 (Brain20, Spine20, Mental20) and Brain Technology and Innovation Park (BTIP) while celebrating pioneers in the fields.

Media Contact
Doreen Santora
201-342-7662
dsantora@bluehorizoninternational.com